- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00260078
Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children
Intensive Pharmacokinetic Studies of Antiretroviral Drug Combinations in Children
연구 개요
상태
정황
상세 설명
Because all of the available non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) are metabolized by and affect hepatic cytochrome enzymes, combinations of two or more of these drugs produce complex pharmacokinetic (PK) interactions. However, little data exist regarding PK of anti-HIV drug combinations in the pediatric population. The purpose of this study is to assess steady-state PK of the following anti-HIV regimens: TDF and EFV or NVP; TDF and DRV with or without EFV; and TDF and RTV with or without EFV. In addition, this study will evaluate how age, length of treatment, adverse effects, and genes affect children's response to different anti-HIV combinations.
This study will last between 1 and 7 weeks. Participants in this study will be grouped based on the treatment regimen they are receiving or about to initiate. There are three groups in this study. Group D participants will receive TDF and EFV or NVP; Group E participants will receive TDF and DRV with or without EFV; and Group F participants will receive TDF and RTV with or without EFV. The inclusion of EFV or NVP will be dependent on each participant's prescribed regimen. Participants within each group will be stratified by age and how long they have been receiving their anti-HIV regimens. Antiretrovirals will not be provided by this study.
Most participants will have two study visits. The first visit will occur at study entry. Medical history, a physical exam, and blood collection will occur. The second visit will occur within 35 days of study entry and will take approximately 24 hours. Blood collection for PK studies, a physical exam, and medical history will be done at this visit. Urine collection will occur at all visits for female participants.
Participants will undergo PK testing at least 14 days after initiating their study regimens. Participants will be given a dose of their anti-HIV medications with food. A blood sample will be taken before dosing. Blood samples will also be taken at 1, 2, 4, 6, 8, 12, and 24 hours after dosing. Participants in Groups E and F may need to repeat PK testing within 6 weeks of initial PK testing at the discretion of the investigator.
연구 유형
등록 (실제)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 장소
-
-
California
-
Alhambra, California, 미국, 91803
- Usc La Nichd Crs
-
La Jolla, California, 미국, 92093-0672
- University of California, UC San Diego CRS
-
Long Beach, California, 미국, 90806
- Miller Children's Hosp. Long Beach CA NICHD CRS
-
Torrance, California, 미국, 90502
- Harbor UCLA Medical Ctr. NICHD CRS
-
-
Connecticut
-
Hartford, Connecticut, 미국, 06106
- Connecticut Children's Med. Ctr.
-
-
Florida
-
Miami, Florida, 미국, 33136
- Pediatric Perinatal HIV Clinical Trials Unit CRS
-
-
Illinois
-
Chicago, Illinois, 미국, 60612
- Rush Univ. Cook County Hosp. Chicago NICHD CRS
-
Chicago, Illinois, 미국, 60614-3393
- Ann & Robert H. Lurie Children's Hospital of Chicago (LCH) CRS
-
-
Maryland
-
Baltimore, Maryland, 미국, 21201
- Univ. of Maryland Baltimore NICHD CRS
-
Baltimore, Maryland, 미국, 21287
- Johns Hopkins Univ. Baltimore NICHD CRS
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02115
- Children's Hosp. of Boston NICHD CRS
-
Springfield, Massachusetts, 미국, 01199
- Baystate Health, Baystate Med. Ctr.
-
Worcester, Massachusetts, 미국, 01605
- WNE Maternal Pediatric Adolescent AIDS CRS
-
-
Michigan
-
Detroit, Michigan, 미국, 48201
- Children's Hospital of Michigan NICHD CRS
-
-
New Jersey
-
Newark, New Jersey, 미국, 07103
- Rutgers - New Jersey Medical School CRS
-
-
New York
-
Bronx, New York, 미국, 10461
- Jacobi Med. Ctr. Bronx NICHD CRS
-
Brooklyn, New York, 미국, 11203
- SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS
-
New York, New York, 미국, 10016
- Nyu Ny Nichd Crs
-
-
North Carolina
-
Durham, North Carolina, 미국, 27710
- DUMC Ped. CRS
-
-
Tennessee
-
Memphis, Tennessee, 미국, 38105-3678
- St. Jude Children's Research Hospital CRS
-
-
Washington
-
Seattle, Washington, 미국, 98105
- Seattle Children's Hospital CRS
-
-
-
-
-
San Juan, 푸에르토 리코, 00936
- San Juan City Hosp. PR NICHD CRS
-
San Juan, 푸에르토 리코, 00935
- University of Puerto Rico Pediatric HIV/AIDS Research Program CRS
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Note: The original Groups A, B, and C have been removed, and Groups D, E, and F have been added per protocol amendment dated 11/16/07.
Inclusion Criteria:
- HIV infected
- Currently receiving or about to initiate one of the following anti-HIV regimens: TDF with EFV or NVP, TDF and DRV/r with or without EFV, or TDF with ATV/r with or without EFV
- Body surface area at least 0.85 m2
- Parent or guardian willing and able to provide signed informed consent
- Willing to use acceptable forms of contraception
Exclusion Criteria:
- Liver disease that may affect the metabolism of study drugs
- Certain abnormal laboratory values
- Require certain medications
- Treatment with any anti-HIV or nonantiretroviral drug that could interact with drugs under PK study in the 14 days prior to study entry
- Any clinical or laboratory toxicity of Grade 4 or higher at screening. More information on this criterion can be found in the protocol.
- Pregnant or breastfeeding
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: D
TDF and EFV or NVP throughout study
|
Dosage dependent on participant
다른 이름들:
Dosage dependent on participant
다른 이름들:
300 mg orally daily
다른 이름들:
Intensive PK study will occur at least once.
This will require a 24-hour inpatient visit.
다른 이름들:
|
|
실험적: E
TDF and DRV with or without EFV throughout study
|
Dosage dependent on participant
다른 이름들:
300 mg orally daily
다른 이름들:
Intensive PK study will occur at least once.
This will require a 24-hour inpatient visit.
다른 이름들:
300 mg or 600 mg orally twice daily
다른 이름들:
50 mg or 100 mg orally twice daily
다른 이름들:
|
|
실험적: F
TDF and ATV and RTV with or without EFV throughout study
|
Dosage dependent on participant
다른 이름들:
300 mg orally daily
다른 이름들:
Intensive PK study will occur at least once.
This will require a 24-hour inpatient visit.
다른 이름들:
50 mg or 100 mg orally twice daily
다른 이름들:
200 mg to 400 mg orally daily
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Predosage concentration (C0 and C12) and area under the concentration-time curve (AUC)
기간: Over the dosing interval
|
Over the dosing interval
|
공동 작업자 및 조사자
수사관
- 연구 의자: Jennifer King, PharmD, Department of Pharmacology and Toxicology, University of Alabama at Birmingham
- 연구 의자: Ram Yogev, MD, Section of Pediatrics and Maternal HIV Infection, Children's Memorial Hospital, Northwestern University Medical School
간행물 및 유용한 링크
일반 간행물
- Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris DR, Havens PL; Adolescent Trials Network for HIV/AIDS Interventions. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob Agents Chemother. 2008 Feb;52(2):631-7. doi: 10.1128/AAC.00761-07. Epub 2007 Nov 19.
- Hazra R, Gafni RI, Maldarelli F, Balis FM, Tullio AN, DeCarlo E, Worrell CJ, Steinberg SM, Flaherty J, Yale K, Kearney BP, Zeichner SL. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics. 2005 Dec;116(6):e846-54. doi: 10.1542/peds.2005-0975. Epub 2005 Nov 15.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- RNA 바이러스 감염
- 바이러스 질환
- 감염
- 혈액 매개 감염
- 전염병
- 성병, 바이러스성
- 성병
- 렌티바이러스 감염
- 레트로바이러스과 감염
- 면역 결핍 증후군
- 면역계 질환
- HIV 감염
- 약리작용의 분자기전
- 항감염제
- 항바이러스제
- 역전사 효소 억제제
- 핵산 합성 억제제
- 효소 억제제
- 항HIV제
- 항레트로바이러스제
- 프로테아제 억제제
- 시토크롬 P-450 CYP3A 억제제
- 시토크롬 P-450 효소 억제제
- 시토크롬 P-450 효소 유도제
- 시토크롬 P-450 CYP3A 유도제
- HIV 프로테아제 억제제
- 바이러스성 프로테아제 억제제
- 사이토크롬 P-450 CYP2B6 유도제
- 시토크롬 P-450 CYP2C9 억제제
- 시토크롬 P-450 CYP2C19 억제제
- 테노포비어
- 네비라핀
- 리토나비어
- 다루나비르
- 아타자나비르 황산염
- 에파비렌즈
기타 연구 ID 번호
- P1058
- 10050 (DAIDS-ES)
- PACTG 1058
- IMPAACT P1058
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .